Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

TCRX - TScan Therapeutics, Inc.

IEX Last Trade
3.02
-0.005   -0.166%

Share volume: 12,905
Last Updated: Fri 27 Dec 2024 08:30:31 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.25%

PREVIOUS CLOSE
CHG
CHG%
$3.02
0.00
-0.17%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
10%
Profitability 0%
Dept financing 11%
Liquidity 75%
Performance 3%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.32%
1 Month
-34.80%
3 Months
-38.29%
6 Months
-50.16%
1 Year
-48.42%
2 Year
108.72%
Key data
Stock price
$3.02
P/E Ratio 
-2.63
DAY RANGE
$2.97 - $3.16
EPS 
-$1.05
52 WEEK RANGE
$3.01 - $9.69
52 WEEK CHANGE
-$46.66
MARKET CAP 
274.166 M
YIELD 
N/A
SHARES OUTSTANDING 
48.697 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
1.26
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$835,609
AVERAGE 30 VOLUME 
$664,105
Company detail
CEO: David P. Southwell
Region: US
Website: tscan.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

TScan Therapeutics, Inc. develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2.

Recent news